DoW Neurofibromatosis Investigator-Initiated Research Award

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features:

• Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community.

• Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists.

The funding levels are defined as follows:

• Level 1: Applications without an optional feature.

• Level 2: Applications including one of the optional features.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Sep 22, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Neurofibromatosis Investigator-Initiated Research Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.